Peginterferon and ribavirin for hepatitis C.
Evoli
Amelia
A
Servidei
Serenella
S
D000328:Adult; D000998:Antiviral Agents / Q000009:adverse effects*; D001327:Autoimmune Diseases / Q000139:chemically induced; D000075202:Contraindications; D004359:Drug Therapy, Combination; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects*; D008297:Male; D009157:Myasthenia Gravis / Q000139:chemically induced*; D011092:Polyethylene Glycols / Q000009:adverse effects*; D011994:Recombinant Proteins; D012254:Ribavirin / Q000627:therapeutic use*
D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C100416:peginterferon alfa-2a